 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming...

Sage Therapeutics to Present at Upcoming September Investor Conferences

Sage Therapeutics (NASDAQ:SAGE  Free Report) had its target price upped by Scotiabank from $24.00 to $27.00 in a research note published on Friday, FlyOnTheWall reports.
SAGE has been the...

Scotiabank Increases Sage Therapeutics (NASDAQ:SAGE) Price Target to $27.00

Sage Therapeutics (NASDAQ:SAGE  Free Report) had its price objective hoisted by Scotiabank from $24.00 to $27.00 in a report issued on Friday morning, FlyOnTheWall reports.
A number of other...

Scotiabank Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $27.00

This is a signal that SAGE's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Sage Therapeutics (SAGE, $20.29) RSI Indicator left the oversold zone on September 01, 2023

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DigitalOcean Holdings...

Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ( Sage or the Company ) (NASDAQ: SAGE). Such investors are...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE

LOS ANGELES, CA / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression (PPD) in late 2023. Our goal is to...

Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch and Pipeline Advancement

Profund Advisors LLC bought a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE  Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities  Exchange Commission. The fund bought 31,144 shares of the biopharmaceutical company...

Profund Advisors LLC Acquires Shares of 31,144 Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. (NASDAQ:SAGE  Get Free Report) saw a significant growth in short interest in August. As of August 15th, there was short interest totalling 9,160,000 shares, a growth of 27.2% from the July 31st total of 7,200,000 shares. Approximately 17.8% of the companys stock...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Sees Significant Increase in Short Interest

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Watchers	6,020
52-Wk Low	$16.52
52-Wk High	$59.99

Market Cap	$1.19B
Volume (M)	154,480.00
52-Wk High	$59.99
52-Wk Low	$16.52

SAGE Sage Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals